Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial

Benzer Materyaller

• Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo‐Controlled Study
  Yazar:: Kavanaugh, Arthur, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Measurement properties of the minimal disease activity criteria for psoriatic arthritis
  Yazar:: Coates, Laura C, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations
  Yazar:: Mease, Philip J., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Patient-Reported Outcomes and the Association With Clinical Response in Patients With Active Psoriatic Arthritis Treated With Golimumab: Findings Through 2 Years of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
  Yazar:: Kavanaugh, Arthur, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis
  Yazar:: Wervers, Kim, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)